Continuous purification method of acidic protein

Through continuous purification method, combined with anion, multimodal and cation exchange chromatography, and using buffers such as acetate, the problems of cumbersome purification steps and incomplete removal of impurities were solved, and efficient and simple purification of recombinant proteins was achieved. Improves purity and yield.

CN119060118AInactive Publication Date: 2024-12-03CHENGDU OLYMVAX BIOPHARM +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411316396.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In the prior art, the purification steps of recombinant protein drugs are complicated, the connection between the front and rear steps is not smooth, the impurities are not thoroughly removed, and the sample purity is not high.

Method used

Continuous purification methods, including anion exchange chromatography, multi-mode chromatography and cation exchange chromatography, use acetate, phosphate or citrate buffer, the pH of the buffer is more than one pH unit higher than the protein isoelectric point, and by The buffer of the same component is connected step by step to avoid precipitation of ammonium sulfate and ultrafiltration liquid replacement.

Benefits of technology

The purification of recombinant proteins with simple operation, high purity and high yield is achieved, reducing the residues of host proteins and nucleic acids, and improving the purification efficiency and purity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060118A_ABST
    Figure CN119060118A_ABST
Patent Text Reader

Abstract

The invention discloses a continuous purification method of acidic protein, the purification step comprises purifying a cell culture supernatant containing acidic protein by using anion exchange chromatography, multi-mode chromatography and cation exchange chromatography in sequence, in anion chromatography, the pH value of a buffer solution is more than one pH unit higher than a protein isoelectric point, and in cation exchange chromatography, the pH value of the buffer solution is more than one pH unit higher than a protein isoelectric point. Target protein is subjected to isocratic elution by salt ions. The method provided by the invention can be used for purifying labeled and non-labeled acidic recombinant proteins, the used buffer system is single, the steps are continuous, repeated liquid change is avoided, compared with the traditional purification steps, the operation is simple and convenient, and the purified recombinant proteins are high in yield, high in purity and low in host protein residual quantity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of acidic protein purification, and in particular to a continuous purification method of acidic protein. Background Art

[0002] Recombinant protein drugs are obtained by using genetic engineering technology to introduce expression vectors carrying target protein genes into host cells for expression, and then undergo a series of purifications. There are many types of recombinant protein drugs, including recombinant enzymes, polypeptide hormones, cytokines, etc. Compared with small molecule chemical drugs, they have stronger specificity, clear biological functions, lower toxicity, and fewer side effects. They are widely used in the fields of tumor and immunotherapy, antiviral therapy, and blood disease treatment.

[0003] Recombinant protein drugs can be expressed in expression systems such as Escherichia coli expression system, yeast expression system, CHO expression system, baculovirus-insect cell expression system, etc. The expressed recombinant protein contains impurities such as culture components, host proteins, host nucleic acids, etc., which may have adverse effects on the human body. Therefore, a series of purification methods are needed to purify the recombinant protein drugs. In addition to the amino acids of the drug itself, new amino acids such as purification tags cannot be introduced into recombinant protein drugs. In addition, the composition of upstream culture products is complex, which greatly increases the difficulty of purifying recombinant protein drugs. The traditional purification steps are long and cumbersome, such as ammonium sulfate precipitation, ultrafiltration and liquid replacement, and repeated adjustment of pH and salt ion concentration. Therefore, it is necessary to develop a purification step with smooth step connection, excellent host impurity removal effect, and high purity. Summary of the invention

[0004] The purpose of the present invention is to provide a continuous purification method for acidic protein to solve the problems of complicated steps, unsmooth connection between previous and subsequent steps, incomplete removal of impurities, low sample purity, etc. in the purification operation in the prior art.

[0005] To achieve the above object, the present invention provides the following technical solutions:

[0006] The present invention provides a method for continuous purification of acidic proteins, wherein the purification step comprises sequentially using anion exchange chromatography, multimodal chromatography and cation exchange chromatography to purify cell culture supernatant containing the acidic proteins, wherein in the anion chromatography, the pH of the buffer solution is higher than the isoelectric point of the protein by more than one pH unit, and the target protein is isocratically eluted by salt ions.

[0007] Furthermore, the buffer involved in the purification process is any one of acetate, phosphate, citrate or phosphate-citrate buffer.

[0008] Furthermore, the concentration range of the buffer solution is 5 to 200 mM.

[0009] Furthermore, in the multimodal chromatography, the equilibration buffer is consistent with the anion elution buffer, the sample after anion purification is directly used for multimodal purification, and the target protein is eluted isocratically by pH.

[0010] Furthermore, the multimodal chromatography is a mode comprising anionic chromatography plus hydrophobic chromatography.

[0011] Furthermore, in the cationic chromatography, the equilibration buffer is consistent with the multimodal chromatography elution buffer, the multimodal purification sample is directly used for cationic chromatography purification, and the target protein is eluted isocratically by pH.

[0012] Based on the above technical solution, the embodiments of the present invention can at least produce the following technical effects:

[0013] (1) The continuous purification method of acidic protein provided by the present invention comprises anion purification, multi-mode purification and cationic purification steps. The same buffer composition is used in the purification process, less materials are used, fewer types of solution preparation are required, no ammonium sulfate precipitation, ultrafiltration and liquid replacement operations are required, and the connection is smooth.

[0014] (2) The continuous purification method of acidic proteins provided by the present invention can purify tagged and untagged acidic recombinant proteins. The buffer system used is single, the steps are continuous, and there is no repeated liquid change. Compared with traditional purification steps, the operation is simple, and the recombinant protein after purification has a high yield, high purity, and low host protein residue. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the structures shown in these drawings without paying creative work.

[0016] Figure 1 This is the SEC-HPLC diagram of the anion purification sample of Example 1 of the present invention;

[0017] Figure 2 This is the SEC-HPLC diagram of the multi-mode purified sample of Example 1 of the present invention;

[0018] Figure 3 This is the SEC-HPLC chart of the cationic purified protein in Example 1 of the present invention. DETAILED DESCRIPTION

[0019] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0020] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0021] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0022] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to the skilled artisan. The present invention description and examples are exemplary only.

[0023] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0024] Example 1

[0025] The recombinant protein purified in this example is varicella-zoster virus glycoprotein E, which has an isoelectric point of about 5.2 and a molecular weight of about 60 kDa.

[0026] 1. Expression of acidic protein

[0027] The CHO cells expressing acidic protein were revived, scaled up step by step in shake flasks, and finally transferred into a 5L bioreactor for culture at a rate of 1×10 6 The culture parameters were as follows: temperature 37°C, pH 7.0, rotation speed 150r / min, dissolved oxygen concentration 40%. Daily sampling was performed to detect cell viability, density, lactic acid content, and glucose content. Fed-batch culture was performed, and feed was added every other day to maintain the glucose content in the culture medium above 2g / L. After about 15 days of culture, when the cell viability dropped to 90%, the culture was terminated. Cells and cell debris were removed by deep filter filtration, and the cell culture supernatant was collected.

[0028] 2. Acidic protein anion purification

[0029] Capto Q anion chromatography filler was used for purification. The column was passed through a pH 6.5 20mM acetic acid equilibrium buffer for more than 5 CVs. The column was balanced to the UV absorption and conductivity baseline levels. The pH was stable. Then the pH was pre-adjusted to 6.5. The cell culture supernatant was passed through the column. After equilibration to the UV absorption baseline level with the same equilibrium buffer, the recombinant target protein was eluted with a pH 6.5 20mM acetic acid elution buffer containing 300mM sodium chloride. The eluted recombinant protein was tested for protein purity, host protein content, and host nucleic acid content. The protein purity test spectrum is shown in the figure below. Figure 1 shown.

[0030] 3. Multi-mode purification of acidic proteins

[0031] Capto adhere multimodal chromatography filler was used for purification. The anion chromatography elution buffer was used as the equilibrium buffer for this step. The column was passed through a pH 6.5 20mM acetic acid equilibrium buffer containing 300mM sodium chloride for more than 5 CVs. The column was balanced to the UV absorption and conductivity baseline levels. The pH was stable. The anion purification product was then directly passed through the column and then balanced to the UV absorption baseline level with the same equilibrium buffer. Finally, the recombinant target protein was eluted with a pH 3.3 20mM acetic acid elution buffer. The eluted recombinant protein was tested for protein purity, host protein content, and host nucleic acid content. The protein purity detection spectrum is shown in the figure below. Figure 2 shown.

[0032] 4. Low pH inactivation of acidic proteins

[0033] The pH range of the recombinant target protein eluted by multi-mode purification is between 3.3 and 3.5, and it is directly placed at room temperature (18-25°C) for 120mMin for inactivation.

[0034] 5. Acidic protein cation purification

[0035] Capto SPImpres cationic filler was used for purification, and the multimodal chromatography elution buffer was used as the equilibrium buffer for this step, and the anion purification equilibrium buffer was used as the elution buffer for this step. The column was passed through a pH 3.3 20mM acetic acid equilibrium buffer for more than 5 CVs, and the layer wash column was balanced to the UV absorption and conductivity baseline levels, and the pH was stable. Then the low pH inactivated product was directly passed through the column, and then balanced to the UV absorption baseline level with the same equilibrium buffer, and finally the recombinant target protein was eluted with a pH 6.5 20mM acetic acid elution buffer. The eluted recombinant protein was tested for protein purity, host protein content, and host nucleic acid content. The protein purity detection spectrum is shown in the figure. Figure 3 shown.

[0036] After three consecutive purification steps, the purity of the recombinant protein reached 99.1%, the host protein residue was less than 0.05%, and the host nucleic acid residue was less than 10pg / 100μg, all meeting the requirements. The specific test results are shown in Table 1.

[0037] Table 1 Recombinant protein purification results

[0038]

[0039] Finally, it should be noted that:

[0040] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that the technical solutions described in the above embodiments may still be modified, or some or all of the technical features may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A method for continuous purification of acidic protein, characterized in that: The purification step includes purifying the cell culture supernatant containing acidic protein by using anion exchange chromatography, multimodal chromatography and cation exchange chromatography successively. In the anion chromatography, the pH of the buffer is higher than the isoelectric point of the protein by more than one pH unit, and the target protein is isocratically eluted by salt ions.

2. The method for continuous purification of acidic protein according to claim 1, characterized in that: The buffer involved in the purification process is any one of acetate, phosphate, citrate or phosphate-citrate buffer.

3. The method for continuous purification of acidic protein according to claim 1, characterized in that: The concentration range of the buffer solution is 5-200 mM.

4. The method for continuous purification of acidic protein according to claim 1, characterized in that: In the multimodal chromatography, the equilibrium buffer is consistent with the anion elution buffer, the sample after anion purification is directly used for multimodal purification, and the target protein is eluted isocratically by pH.

5. The method for continuous purification of acidic protein according to claim 1, characterized in that: The multimodal chromatography is a mode comprising anionic chromatography plus hydrophobic chromatography.

6. The method for continuous purification of acidic protein according to claim 1, characterized in that: In the cationic chromatography, the equilibrium buffer is consistent with the multimodal chromatography elution buffer, the multimodal purification sample is directly used for cationic chromatography purification, and the target protein is eluted isocratically by pH.

Citation Information

Patent Citations

  • Method for purifying fusion proteins having igg fc domain

    CN118414350A

  • Method for purifying recombinant protein

    CN118459537A

  • Method for purifying fusion protein of recombinant human serum albumin

    WO2023024214A1